Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy

Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma

(2018) Ajai Chari et al.   Clinical Lymphoma Myeloma & Leukemia

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

(2018) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

(2016) Saad Z. Usmani et al.   BLOOD

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

(2016) A. Jakubowiak et al.   BLOOD

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

(2016) Inger S. Nijhof et al.   BLOOD

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

(2016) Jesus Berdeja et al.   Clinical Lymphoma Myeloma & Leukemia

New mAb therapies in multiple myeloma

(2016) Karen M.K. De Vooght et al.   CURRENT OPINION IN HEMATOLOGY

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

(2015) N. W. C. J. van de Donk et al.   BLOOD

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

(2015) J. P. Laubach et al.   CLINICAL CANCER RESEARCH

Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)

(2015) M. Dimopoulos et al.   Clinical Lymphoma Myeloma & Leukemia

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

(2015) I S Nijhof et al.   LEUKEMIA

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

(2015) Marije B Overdijk et al.   mAbs

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma

(2015) Judith L. Hannon et al.   TRANSFUSION

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy

(2015) Marlies Oostendorp et al.   TRANSFUSION

Resolving the daratumumab interference with blood compatibility testing

(2015) Claudia I. Chapuy et al.   TRANSFUSION

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

(2015) Paul G Richardson et al.   Lancet Haematology

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy

(2015) Anne-Marit Sponaas et al.   PLoS One

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

(2014) P. G. Richardson et al.   BLOOD

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma

(2013) André Veillette et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

(2012) Andrzej J. Jakubowiak et al.   JOURNAL OF CLINICAL ONCOLOGY

Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

(2012) Sagar Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

CD38 and chronic lymphocytic leukemia: a decade later

(2011) F. Malavasi et al.   BLOOD

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

(2011) J. A. Zonder et al.   BLOOD

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

(2011) M S van der Veer et al.   Blood Cancer Journal

Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease

(2010) A. Aouba et al.   BLOOD

Unknown

(2009) Alberto Horenstein et al.   MOLECULAR MEDICINE

Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function

(2009) Mario-Ernesto Cruz-Munoz et al.   NATURE IMMUNOLOGY

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

(2008) E. D. Hsi et al.   CLINICAL CANCER RESEARCH

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

(2007) Y.-T. Tai et al.   BLOOD